Clinical trials
Advanced Malignant Cancer clinical trials
Below are recruiting advanced malignant cancer clinical trials, each written for real people, not researchers. We’re tracking 1,520 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07006077RecruitingPhase 2
Investigational virus injection for advanced pancreatic cancer
This trial tests a new treatment that uses a virus to attack tumor cells directly. It is for people with advanced pancreatic cancer that has not responded to standard therapy. The virus is injected into a tumor, and the goal is to see if it can shrink the cancer or slow its growth.
Hangzhou, ZhejiangAges 18–75 - NCT06945523RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced lung cancer
This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.
Wuhan, HubeiAges 18 years+ - NCT06770439RecruitingPhase 2
New drug plus chemotherapy for advanced pancreatic cancer
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18 years+ - NCT03878849RecruitingPhase 2
Study drug 2X-121 for ovarian cancer that keeps coming back
This Phase 2 trial tests whether 2X-121 can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum chemotherapy. It enrolls people who have had limited prior treatment and can provide a recent or stored tumor sample.
Oklahoma City, OklahomaAges 18 years+ - NCT06433609RecruitingPhase 2
ADC plus immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Gilbert, ArizonaAges 18 years+ - NCT06335914Recruiting
Dual PET scans for advanced prostate cancer
This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.
Toronto, OntarioAges 18 years+ - NCT06028074RecruitingPhase 1/Phase 2
Study of GIM-122 for advanced solid tumors
This trial tests a new drug, GIM-122, in people with advanced solid tumors that have stopped responding to or cannot tolerate standard PD-1/PD-L1 inhibitors. The goal is to see if GIM-122 is safe and tolerable.
Los Angeles, CaliforniaAges 18 years+ - NCT05142475RecruitingEarly Phase 1
Study of GC101 tumor-infiltrating cells for advanced breast cancer
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
ShanghaiAges 18–75 - NCT05112991RecruitingPhase 2
Check whether envafolimab plus lenvatinib helps advanced uterine cancer
This Phase 2 trial tests whether envafolimab alone or combined with lenvatinib can slow or shrink advanced endometrial (uterine) cancer. It’s for people whose cancer has grown again or spread and who didn’t do well with standard platinum chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07024173RecruitingPhase 3
HRS-8080 versus doctor's choice for advanced breast cancer
This trial tests a new medicine called HRS-8080 for locally advanced or metastatic breast cancer. It compares HRS-8080 with whatever treatment your doctor would normally choose for you.
Guangzhou, GuangdongAges 18–75 - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT07763301RecruitingPhase 1
Vaccine for advanced liver, bile duct, or pancreatic cancer
This trial is testing an investigational vaccine (YMN-136) for people with advanced liver, bile duct, or pancreatic cancer that has not responded to standard treatments or is not tolerated. The vaccine aims to help your immune system fight the cancer. It may be an option if standard treatments have failed.
Chengdu, SichuanAges 18–75 - NCT05438459RecruitingPhase 1/Phase 2
GAIA-102 for advanced stomach or pancreatic cancer with ascites
This trial tests a new drug, GAIA-102, given directly into the abdomen to treat advanced stomach or pancreatic cancer that has spread to the belly lining and causes fluid buildup (malignant ascites). The goal is to see if it can slow the cancer or improve symptoms.
Fukuoka, FukuokaAges 20 years+ - NCT05406999RecruitingPhase 2
Intense hormone treatment before prostate surgery for high-risk cancer
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
Nanjing, JiangsuAges 18–80 - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT07192120RecruitingPhase 1/Phase 2
MHB048C for advanced solid tumors
This trial is testing a new medicine called MHB048C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06912152RecruitingPhase 1
Testing MT027 for advanced belly-lining cancers
This trial tests an experimental intraperitoneal therapy (MT027) for people whose advanced solid tumors have spread to the lining of the belly (peritoneum) and haven't responded to standard treatments. It aims to see if this new approach can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT07040098RecruitingPhase 2
Optimizing immunotherapy with chemo-radiation for rectal cancer
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
BeijingAges 18–75 - NCT06486883RecruitingPhase 2
T-DXd vs CDK4/6i plus hormone therapy for advanced HR-positive, HER2-low breast cancer
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
GrazAges 18 years+ - NCT07876154RecruitingPhase 2
Immunotherapy plus chemo before surgery for locally advanced cervical cancer
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
Xi'an, ShaanxiAges 18–70 - NCT05300269RecruitingPhase 2
Test drug SHR-1701 with chemo and radiation for rectal cancer
This trial studies whether adding SHR-1701 to standard chemotherapy and long-course radiation can improve treatment for locally advanced rectal cancer that can be removed by surgery. It’s mainly for people who have not had prior rectal cancer treatment and who fit several health and cancer-spread requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05378087Recruiting
Compare two ways to plan treatment for cervical cancer
This study compares two staging methods—using surgery results versus imaging tests—to help doctors plan treatment for locally advanced cervical cancer. It may improve how accurately the cancer is mapped, which could affect treatment choices and outcomes.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05245474RecruitingPhase 2
Before-surgery chemoradiation plus PD-1 for locally advanced rectal cancer
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Advanced Malignant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant cancer?
- Yes. Clin2 currently lists 1,520 recruiting advanced malignant cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.